THE INGREDIENT, IN FOCUS
CJC-1295: biology and human evidence
A peptide designed to act on the system that releases growth hormone. Its exact form matters. The catalogue does not state DAC or no-DAC for PrimeBuild. Research on long-acting albumin-binding CJC-1295 does not identify this product’s material.
The biology, in plain words.
CJC-1295 is based on growth-hormone-releasing hormone, or GHRH. GHRH acts at the pituitary gland, a small gland that sends hormone signals. Growth hormone can in turn affect IGF-I, another signal involved in growth. The studied long-acting CJC form has an albumin-binding chemical feature called DAC. Albumin is a common blood protein. An unspecified CJC label does not establish whether that feature is present; modified GRF(1–29) is often sold under a no-DAC label. DAC stands for drug affinity complex. Binding to albumin can change how quickly a peptide leaves circulation.
The 2006 studies followed hormone effects over 28 and 49 days. The endpoints concerned exposure to the peptide and changes in GH and IGF-I. Short monitoring without a serious event is not the same as evidence about long-term use, uncommon harms or a desired change in body composition.
What the studies found.
Two short randomized trials of long-acting CJC-1295 measured hormone levels. GH and IGF-I rose for days. The trials did not establish improved muscle size, sleep or healthy aging, and they did not test a CJC/Ipamorelin blend.
Details that change the comparison.
The DAC form and products called no-DAC are not interchangeable labels. The original long-acting research used an albumin-binding molecule. Modified GRF(1–29) is commonly sold under a no-DAC description, so the full structure matters more than a short product title. The proposed PrimeBuild specification leaves this point open, while BioFrontier names DAC.
Growth hormone, IGF-I and a measured gain in muscle are different endpoints. A higher marker does not tell us the balance of benefits and harms over time. Ipamorelin reaches the system through a different receptor, and a combination needs its own evidence rather than adding the conclusions of separate papers.
Sources behind this profile.
Sources checked . Written by GotPeptide. No independent clinician review.